GSK2801inhibitor of BAZ2A and BAZ2B bromodomains CAS# 1619994-68-1 |
- PF-04691502
Catalog No.:BCC3837
CAS No.:1013101-36-4
- NVP-BGT226
Catalog No.:BCC3827
CAS No.:1245537-68-1
- HS-173
Catalog No.:BCC5363
CAS No.:1276110-06-5
- CUDC-907
Catalog No.:BCC2154
CAS No.:1339928-25-4
- PIK-93
Catalog No.:BCC2519
CAS No.:593960-11-3
- XL147
Catalog No.:BCC2487
CAS No.:956958-53-5
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1619994-68-1 | SDF | Download SDF |
PubChem ID | 73010930 | Appearance | Powder |
Formula | C20H21NO4S | M.Wt | 371.45 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 50 mg/mL (134.61 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
Chemical Name | 1-[1-(2-methylsulfonylphenyl)-7-propoxyindolizin-3-yl]ethanone | ||
SMILES | CCCOC1=CC2=C(C=C(N2C=C1)C(=O)C)C3=CC=CC=C3S(=O)(=O)C | ||
Standard InChIKey | KHWCPNJRJCNVRI-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C20H21NO4S/c1-4-11-25-15-9-10-21-18(14(2)22)13-17(19(21)12-15)16-7-5-6-8-20(16)26(3,23)24/h5-10,12-13H,4,11H2,1-3H3 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective BAZ2A and BAZ2B inhibitor (IC50 values are 0.40 and 0.43 μM, respectively). Selective for BAZ2A/B over TAF1L and BRD9. Cell permeable and orally available. |
GSK2801 Dilution Calculator
GSK2801 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.6922 mL | 13.4608 mL | 26.9215 mL | 53.843 mL | 67.3038 mL |
5 mM | 0.5384 mL | 2.6922 mL | 5.3843 mL | 10.7686 mL | 13.4608 mL |
10 mM | 0.2692 mL | 1.3461 mL | 2.6922 mL | 5.3843 mL | 6.7304 mL |
50 mM | 0.0538 mL | 0.2692 mL | 0.5384 mL | 1.0769 mL | 1.3461 mL |
100 mM | 0.0269 mL | 0.1346 mL | 0.2692 mL | 0.5384 mL | 0.673 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
GSK2801, as an inhibitor of BAZ2A and BAZ2B bromodomains, is potent, selective and cell active acetyl-lysine competitive, with dissociation constants (KD) of 136 and 257 nM for binding to BAZ2B and BAZ2A, respectively [1].
Bromodomains, as protein interaction domains, are acetyl-lysine specific. Bromodomain containing proteins BAZ2A and BAZ2B are closely related. The nucleolar remodeling complex (NoRC) regulates the expression of noncoding RNAs. BAZ2A and BAZ2B constitute the central scaffolding protein of NoRC [1].
In U2OS cells, treatment with the SAHA induced hyperacetylated chromatin. In a GFP-BAZ2A fusion construct, the conserved asparagines that are essential for recognizing the acetylated lysine has been mutated. When a GFP-BAZ2A fusion construct was transfected into SAHA-treated U2OS cells, the mutant construct accelerated FRAP half-recovery time. Treatment with GSK2801 alone in U2OS cells also accelerated FRAP half-recovery time. Both acceleration extents are the same. This meant that GSK2801 can displace BAZ2A from chromatin [1].
Pharmacokinetic parameters of GSK2801 after intraperitoneal and oral dosing to male CD1 mice were measured. Data showed that after oral dosing in vivo, GSK2801 has reasonable exposure, reasonable plasma stability and modest clearance. GSK2801 can be used as an inhibitor of BAZ2A/B bromodomain in vivo [1]. No more in vivo data of the treatment with GSK2801 are found.
Reference:
[1]. Chen P, Chaikuad A, Bamborough P, et al. Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B. Journal of medicinal chemistry, 2015.
- LY2857785
Catalog No.:BCC8050
CAS No.:1619903-54-6
- Catechin pentaacetate
Catalog No.:BCN1718
CAS No.:16198-01-9
- Esomeprazole Magnesium
Catalog No.:BCC5007
CAS No.:161973-10-0
- Prehelminthosporol
Catalog No.:BCN7447
CAS No.:1619-13-2
- Segetalin A
Catalog No.:BCC9246
CAS No.:161875-97-4
- Talampanel(LY300164)
Catalog No.:BCC6378
CAS No.:161832-65-1
- Amprenavir (agenerase)
Catalog No.:BCC3619
CAS No.:161814-49-9
- Benzamil
Catalog No.:BCC7674
CAS No.:161804-20-2
- Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methyl-1,3-thiazole-5-carboxylate
Catalog No.:BCC8966
CAS No.:161798-02-3
- Ethyl 2-(3-formyl-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate
Catalog No.:BCC8968
CAS No.:161798-01-2
- Ethyl 2-(4-hydroxyphenyl)-4-methylthiazole-5-carboxylate
Catalog No.:BCC8969
CAS No.:161797-99-5
- Esomeprazole Sodium
Catalog No.:BCC4376
CAS No.:161796-78-7
- Bromosporine
Catalog No.:BCC2226
CAS No.:1619994-69-2
- Rofecoxib
Catalog No.:BCC4437
CAS No.:162011-90-7
- UNC0379
Catalog No.:BCC8055
CAS No.:1620401-82-2
- L-371,257
Catalog No.:BCC7353
CAS No.:162042-44-6
- SC 58125
Catalog No.:BCC5948
CAS No.:162054-19-5
- Myriceric acid C
Catalog No.:BCN1719
CAS No.:162059-94-1
- Dimesna
Catalog No.:BCC1095
CAS No.:16208-51-8
- 4',4'''-Di-O-methylisochamaejasmin
Catalog No.:BCN6849
CAS No.:1620921-68-7
- SynaptoRedTM C2
Catalog No.:BCC8012
CAS No.:162112-35-8
- RWJ 50271
Catalog No.:BCC7894
CAS No.:162112-37-0
- Flunitrazepam
Catalog No.:BCC6107
CAS No.:1622-62-4
- Melperone hydrochloride
Catalog No.:BCC7385
CAS No.:1622-79-3
Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.[Pubmed:25799074]
J Med Chem. 2016 Feb 25;59(4):1410-24.
Bromodomains are acetyl-lysine specific protein interaction domains that have recently emerged as a new target class for the development of inhibitors that modulate gene transcription. The two closely related bromodomain containing proteins BAZ2A and BAZ2B constitute the central scaffolding protein of the nucleolar remodeling complex (NoRC) that regulates the expression of noncoding RNAs. However, BAZ2 bromodomains have low predicted druggability and so far no selective inhibitors have been published. Here we report the development of GSK2801, a potent, selective and cell active acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains as well as the inactive control compound GSK8573. GSK2801 binds to BAZ2 bromodomains with dissociation constants (KD) of 136 and 257 nM for BAZ2B and BAZ2A, respectively. Crystal structures demonstrated a canonical acetyl-lysine competitive binding mode. Cellular activity was demonstrated using fluorescent recovery after photobleaching (FRAP) monitoring displacement of GFP-BAZ2A from acetylated chromatin. A pharmacokinetic study in mice showed that GSK2801 had reasonable in vivo exposure after oral dosing, with modest clearance and reasonable plasma stability. Thus, GSK2801 represents a versatile tool compound for cellular and in vivo studies to understand the role of BAZ2 bromodomains in chromatin biology.